Don't worry about our $19B bond issue, BMS says. With Celgene, we'll have the cash to pay it off

Bristol-Myers Squibb is taking on a debt load to cover its $74 billion Celgene buyout, and it issued $19 billion in bonds Tuesday to help pay the bill. But with billions in cash flow on tap, BMS doesn't plan to carry that burden for long.